TRAF3 Haploinsufficiency: Comprehensive Disease Research Report

1. Disease Information

Overview. TRAF3 haploinsufficiency (TRAF3-HI, also cataloged as Immunodeficiency-132B / IMD132B) is a recently delineated (2022–2024) autosomal dominant monogenic immune dysregulation syndrome caused by heterozygous loss-of-function variants in TRAF3 (TNF Receptor-Associated Factor 3, chromosome 14q32.32). It is distinct from — but mechanistically related to — an earlier-described entity, Immunodeficiency-132A (IMD132A), caused by a dominant-negative (rather than simple loss-of-function/haploinsufficient) TRAF3 variant and first linked to susceptibility to herpes simplex encephalitis (HSE) (Pérez de Diego et al., 2010, PMID 20832341; OMIM #614849).

TRAF3-HI/IMD132B was formally characterized in a 2022 Science Immunology study of 9 individuals from 5 unrelated families (Wan/Uzel et al., PMID unlisted directly but DOI 10.1126/sciimmunol.abn3800; OMIM #621096), and expanded in a 2024 Journal of Clinical Immunology cohort study (Urban et al., PMID 39579173) that used a TRAF3-targeted reanalysis of next-generation sequencing data from 800 inborn-errors-of-immunity (IEI) patients, identifying 3 additional patients in 2 families who had previously carried a diagnosis of common variable immunodeficiency (CVID).

Key identifiers: - OMIM (phenotype): #621096 (IMD132B, TRAF3-HI; loss-of-function) and #614849 (IMD132A; dominant-negative) - OMIM (gene): 601896 — TNF Receptor-Associated Factor 3; TRAF3 - Gene location: 14q32.32 - MalaCards: "Immunodeficiency 132B" - MONDO: No stable, indexed MONDO term was retrievable via search at the time of this report (the entity is very recently described; Mondo/Monarch integration may lag behind the 2022–2024 primary literature — this should be verified directly against a current Mondo release before curation, as no confirmed MONDO CURIE could be established from available sources) - HGNC:* TRAF3 (gene ID for the causal gene)

Synonyms: TRAF3 deficiency; TRAF3 haploinsufficiency syndrome (TRAF3-HI); Immunodeficiency 132B (IMD132B); CD40-associated protein 1 / CAP-1 (historical alternate gene name); LAP1 (historical alternate gene name).

Data derivation: Almost all clinical characterization comes from aggregated case series (9 patients/5 families in the founding paper; 3 more patients/2 families in the follow-up cohort study derived from an 800-patient IEI sequencing registry) rather than large-scale EHR/population data, consistent with an ultra-rare, newly described monogenic disorder.

2. Etiology

Disease Causal Factors

TRAF3-HI is caused by heterozygous loss-of-function (LOF) variants in TRAF3 (premature stop-codon/nonsense, frameshift) that reduce TRAF3 mRNA and protein to roughly half of normal levels in patient PBMCs — true haploinsufficiency, as opposed to the dominant-negative missense mechanism of IMD132A. Reported LOF variants include stop-gain mutations p.Arg163* and p.Gln407* (Urban et al., 2024, PMID 39579173).

By contrast, IMD132A is caused by a de novo dominant-negative missense variant, c.352C>T (p.Arg118Trp, R118W), in the first of TRAF3's five zinc-finger domains; Western blot in the index patient showed TRAF3 protein reduced to ~17.5% of control levels — far below the ~50% expected from simple haploinsufficiency — indicating the mutant protein actively destabilizes wild-type TRAF3 (dominant-negative interference) (PMID 20832341; OMIM #614849). A second dominant-negative variant, R338W, has been reported in a patient with chronic pulmonary Mycobacterium abscessus infection (Open Forum Infect Dis, PMID 36004314).

Risk Factors

• Genetic: Inheritance of a heterozygous LOF or dominant-negative TRAF3 allele is both necessary and sufficient risk. No modifier genes are yet established, though variable expressivity within families (see Inheritance section) implies unidentified genetic or environmental modifiers.
• Age: A 2025 PNAS study (Hornick et al., PMID 40773231) found that TRAF3 protein (but not mRNA) declines with normal aging in human B cells — comparing donors over 65 vs. under 32 years — via proteasome-mediated (bortezomib-reversible) degradation rather than transcriptional loss. This suggests age itself is a "second hit" that phenocopies genetic haploinsufficiency, plausibly explaining age-related increases in B-cell hyperactivity and B-cell malignancy risk in the general population, and predicting that TRAF3-HI patients' phenotypes may worsen with age.
• Chronic receptor engagement: Sustained CD40 ligand (CD40L) signaling — as occurs in lupus and Sjögren's disease — drives ongoing TRAF3 degradation and could compound genetic deficiency.

Protective Factors

No specific genetic or environmental protective factors have been identified in the literature to date.

Gene-Environment Interactions

The clearest documented interaction is the convergence of chronic B-cell-receptor pathway signaling (CD40, BAFF-R/TNFRSF13C) with reduced TRAF3 dosage: BAFF-receptor stimulation causes sustained TRAF3 reduction (>72 hours) while CD40 stimulation causes transient reduction (recovery by 24h), but both converge on NF-κB2 (non-canonical) activation — meaning inflammatory/infectious triggers that engage these receptors chronically could exacerbate B-cell dysregulation in genetically haploinsufficient individuals (PMID 40773231).

3. Phenotypes

TRAF3-HI presents as a complex, variably expressive immune dysregulation syndrome combining immunodeficiency, autoimmunity, and lymphoproliferation — a triad increasingly recognized across NF-κB pathway primary immunodeficiencies.

Core/consistent features (IMD132B): - Recurrent upper and lower respiratory tract infections with diverse pathogens, onset in childhood — HPO: Recurrent respiratory infections (HP:0002205) - Bronchiectasis — HPO: Bronchiectasis (HP:0002110) (documented in a 36-year-old male index patient with lifelong sinopulmonary infections) - B-cell lymphoid hyperplasia / lymphoproliferation — HPO: Lymphoproliferative disorder-adjacent terms; Lymphadenopathy (HP:0002716) - T-cell subset dysregulation — low/mildly reduced CD4+ T-cell counts, decreased naive T cells, increased CD4+ memory T cells, variably increased regulatory T cells (Tregs), increased circulating T follicular helper (Tfh) cells, and impaired T-cell proliferative responses

Variable features: - Autoimmune disease with autoantibodies (e.g., autoimmune hepatitis-type presentations, cytopenias reported across the NF-κB-PID literature) — HPO: Autoimmunity (HP:0002960) - Systemic autoinflammation - Gastrointestinal inflammation — one index patient had ileitis and chronic active pancolitis — HPO: Inflammation of the large intestine (HP:0002037)/Ileitis - Hepatosplenomegaly — HPO: Hepatosplenomegaly (HP:0001433); the index 36-year-old also had nodular lymphoid hyperplasia - B-cell maturation defects: reduced class-switched memory B cells, increased naive B cells - Dysgammaglobulinemia: hyper- or hypogammaglobulinemia (both directions reported) — HPO: Hypergammaglobulinemia (HP:0010702) / Hypogammaglobulinemia (HP:0004313) - Increased risk of B-cell malignancy (see Prognosis section)

IMD132A-specific phenotype (dominant-negative form): - Herpes simplex encephalitis (HSE) in childhood — HPO: Encephalitis (HP:0002383); impaired TLR3-dependent interferon-β and IL-6 production upon poly(I:C) stimulation - Chronic pulmonary Mycobacterium abscessus infection, treatment-resistant, reported in an adult patient — HPO: Recurrent bronchitis/Nontuberculous mycobacterial infection

Age of onset: Predominantly childhood for the core immunodeficiency/lymphoproliferative phenotype; some manifestations (e.g., chronic M. abscessus infection) present in adulthood.

Severity/progression: Variable and progressive in at least some patients (bronchiectasis implies cumulative structural lung damage from recurrent infection); course is chronic/lifelong.

Quality of life impact: Not formally quantified in the literature (no EQ-5D/SF-36 data identified); qualitatively, the combination of recurrent infection, chronic GI inflammation, and immunoglobulin-replacement dependence implies substantial burden, consistent with other CVID-spectrum disorders.

4. Genetic/Molecular Information

Causal gene: TRAF3 (HGNC symbol TRAF3; historically CAP1, LAP1), 14q32.32, OMIM *601896.

Variant classes reported:

Protein domain architecture: TRAF3 has an N-terminal RING-type zinc-finger domain (required for TRAF3's role in downregulating NF-κB2/p100 processing) and additional zinc fingers, followed by a C-terminal MATH/TRAF domain, which mediates receptor binding — the crystal structure of the CD40 cytoplasmic tail bound to the TRAF3 MATH domain shows the CD40 peptide binding as a hairpin loop across the domain surface.

Functional consequence: functional_impact_category-relevant — LOF variants → LOSS_OF_FUNCTION (haploinsufficiency, ~50% protein/mRNA reduction); R118W and R338W → DOMINANT_NEGATIVE (disproportionate reduction of total TRAF3 below the 50% haploinsufficiency threshold via interference with wild-type protein).

Population frequency / ClinVar: ClinVar records specific TRAF3 variants under "Herpes simplex encephalitis, susceptibility to, 3" (e.g., NM_145725.3:c.810C>T and c.651+13G>C). No large-scale gnomAD constraint or general-population carrier-frequency statistic specific to disease-causing LOF alleles was retrieved; TRAF3 is broadly conserved and intolerant of loss-of-function based on its essential immune-regulatory role (inferred from mouse knockout lethality, below).

Somatic vs. germline distinction: Germline heterozygous LOF/dominant-negative variants cause the Mendelian immunodeficiency syndrome. Separately, somatic homozygous deletions and inactivating mutations of TRAF3 are well documented as recurrent, non-germline drivers in multiple myeloma and B-cell non-Hodgkin lymphoma, where TRAF3 behaves as a bona fide tumor suppressor via constitutive non-canonical NF-κB activation. This is mechanistically related but etiologically distinct from the germline haploinsufficiency syndrome.

Epigenetics: No disease-specific DNA methylation/histone data were identified; however, the 2025 PNAS aging study shows TRAF3 protein (not mRNA) declines with age via proteasomal degradation, a post-translational rather than epigenetic mechanism.

Chromosomal abnormalities: No recurrent aneuploidy/translocation involving 14q32.32 is described for the germline syndrome (distinct from the well-known 14q32 IGH translocations in B-cell malignancy, which is a different genomic phenomenon).

5. Environmental Information

• Infectious triggers: Herpes simplex virus-1 is the specific documented trigger for encephalitis in IMD132A; Mycobacterium abscessus is documented as a chronic pulmonary pathogen in TRAF3-deficient patients. Diverse unspecified bacterial/viral pathogens drive the recurrent sinopulmonary infections seen in IMD132B.
• Lifestyle/toxin factors: None specifically implicated in the literature reviewed.
• No infectious cause of the underlying disease itself is implicated (this is a monogenic immunodeficiency, not an infection-triggered disease); rather, infection is a downstream phenotypic consequence of the impaired antiviral/antibacterial immune signaling.

6. Mechanism / Pathophysiology

Molecular pathway

TRAF3 is a cytoplasmic adaptor that functions downstream of CD40, BAFF-receptor (BAFF-R/TNFRSF13C), other TNFR-superfamily members, TLR3/TRIF, and RIG-I-like receptors. Its central, disease-relevant role is as a negative regulator of the non-canonical (alternative) NF-κB2 pathway: together with TRAF2 and cIAP1/2, TRAF3 constitutively targets NIK (NF-κB-inducing kinase) for K48-linked polyubiquitination and proteasomal degradation, keeping NF-κB2/p100→p52 processing suppressed at baseline. Receptor engagement (CD40L, BAFF) triggers TRAF3's own K48-ubiquitination and degradation, releasing NIK, and permitting NF-κB2 (p52) activation and downstream B-cell survival/differentiation signaling. TRAF3 also participates in TLR3-TRIF-dependent type I interferon induction (IFN-β) relevant to antiviral defense (PMID 20832341) and in canonical NF-κB/MAPK regulation more broadly.

Causal chain (haploinsufficiency form, IMD132B)

1. Trigger: Heterozygous LOF TRAF3 variant → ~50% reduction in TRAF3 protein/mRNA in B cells and PBMCs.
2. Molecular consequence: Insufficient TRAF3-TRAF2-cIAP degradation of NIK → increased basal and receptor-stimulated non-canonical NF-κB2 (p52) activation — shown to be "significantly more abundant" in heterozygous mouse B cells vs. wild-type, at levels intermediate between wild-type and complete knockout.
3. Downstream transcriptional/metabolic effects: Dose-dependent elevation of pro-survival proteins Mcl1, Pim2, c-Myc, and the glycolytic enzyme Hxk2; increased mitochondrial respiration; heightened phospho-STAT3 (Y705) signaling downstream of IL-6 receptor engagement.
4. Cellular consequence: Prolonged B-cell survival in vitro (heterozygous B cells outlive wild-type through day 3 of culture before dying by day 5), increased splenic B-cell numbers and plasma cells (splenic but not bone-marrow), and altered B-cell maturation (reduced class-switched memory B cells, increased naive B cells) in humans.
5. Tissue/organism consequence: B-cell hyperactivity → hypergammaglobulinemia and autoimmunity (autoantibody production, lymphoid hyperplasia, GI inflammation, hepatosplenomegaly) coexisting paradoxically with impaired pathogen clearance (recurrent respiratory infection) — attributable to concurrent T-cell dysregulation (reduced naive T cells, impaired T-cell proliferation) and disrupted humoral maturation despite B-cell numeric expansion.
6. Malignancy risk: Chronic non-canonical NF-κB2 hyperactivation and elevated pro-survival/proliferative signaling (Mcl1, c-Myc, Pim2) create a cell-intrinsic substrate for B-cell malignant transformation, mirroring the well-established role of complete/biallelic somatic TRAF3 loss as an oncogenic driver in multiple myeloma and B-cell lymphoma.

Dominant-negative form (IMD132A)

Rather than simple dosage reduction, mutant TRAF3 protein (e.g., R118W) destabilizes the wild-type protein produced from the normal allele, driving TRAF3 levels far below the 50% haploinsufficiency threshold. This severely impairs TLR3/TRIF-dependent IFN-β and IL-6 production, compromising CNS antiviral defense against HSV-1 and predisposing to herpes simplex encephalitis; a distinct manifestation involves impaired antimycobacterial TNF-α-dependent responses, predisposing to chronic M. abscessus pulmonary infection.

Cell types and biological processes involved

• Cell types (CL terms): B lymphocyte (CL:0000236), plasma cell (CL:0000786), naive B cell (CL:0000788), memory B cell (CL:0000787), CD4+ T cell (CL:0000624), regulatory T cell (CL:0000815), T follicular helper cell (CL:0002038)
• Biological processes (GO terms): non-canonical NF-kappaB signal transduction (GO:0038061 / related to GO:0043123 positive regulation of NF-kB), protein K48-linked ubiquitination (GO:0070936), toll-like receptor 3 signaling pathway (GO:0034138), type I interferon production, B cell proliferation (GO:0042100), B cell differentiation, mitochondrial respiration/oxidative phosphorylation

Molecular profiling

No published transcriptomic (GEO), proteomic, or single-cell datasets specific to human TRAF3-HI patients were identified in this search; the mechanistic dataset is largely built from B-cell-conditional Traf3 knockout/heterozygous mouse models (B-Traf3+/−) combined with patient PBMC/B-cell immunophenotyping (flow cytometry, Western blot) rather than omics-scale profiling.

7. Anatomical Structures Affected

• Organ level: Primary — respiratory tract (recurrent infection, bronchiectasis), lymphoid organs (spleen, lymph nodes — lymphadenopathy, splenomegaly), liver (hepatomegaly, possible autoimmune hepatitis-type involvement), gastrointestinal tract (ileitis, pancolitis). CNS involvement (encephalitis) specific to the IMD132A/HSE phenotype.
• Body systems: Immune system (primary), respiratory system, hepatobiliary system, gastrointestinal system, and secondarily the central nervous system in the dominant-negative HSE-associated form.
• Tissue/cell level: Lymphoid tissue (nodular lymphoid hyperplasia), B-lymphocyte and T-lymphocyte compartments specifically.
• Subcellular: Cytoplasmic signalosome complexes (TRAF3-TRAF2-cIAP1/2-NIK) at the plasma membrane/receptor complex; proteasome-mediated degradation machinery.
• UBERON-relevant sites: spleen (UBERON:0002106), lymph node (UBERON:0000029), lung (UBERON:0002048), liver (UBERON:0002107), large intestine (UBERON:0000059), ileum (UBERON:0002116).

8. Temporal Development

• Onset: Predominantly childhood for the core immunodeficiency phenotype (recurrent respiratory infections, bronchiectasis by adulthood implies childhood onset); HSE onset also in childhood (IMD132A); M. abscessus pulmonary infection described in an adult (51-year-old woman).
• Progression: Chronic, apparently progressive in respiratory (structural bronchiectasis) and possibly hepatic/GI domains; not described as episodic overall, though autoimmune flares may be episodic in nature (consistent with other autoimmune-lymphoproliferative PIDs).
• Course: Lifelong/chronic — no spontaneous remission described. The 2025 aging data suggest phenotype severity could plausibly worsen with advancing age due to superimposed age-related TRAF3 protein decline, though this has not been formally studied longitudinally in patients.

9. Inheritance and Population

• Epidemiology: Ultra-rare; only ~12 patients (9 in the founding cohort + 3 in the follow-up CVID-reanalysis cohort) are documented in the literature reviewed for the haploinsufficiency (IMD132B) form as of this report, plus a small number of additional IMD132A (dominant-negative) cases (HSE and M. abscessus presentations). No formal prevalence/incidence estimate exists.
• Inheritance pattern: Autosomal dominant for both IMD132A and IMD132B.
• Penetrance/expressivity: Variable expressivity is evident — patients within and across families present with differing combinations of infection, autoimmunity, and lymphoproliferation; some previously carried alternate diagnoses (e.g., CVID) before TRAF3 variants were identified via targeted reanalysis, suggesting either incomplete ascertainment of the syndrome's distinctive features or genuinely variable presentation.
• De novo occurrence: The prototypic IMD132A R118W variant arose de novo.
• Founder effects/consanguinity/carrier frequency: Not reported; not applicable given autosomal dominant, non-recessive inheritance.
• Sex ratio: Not explicitly reported as skewed in available sources (index patients described include both male and female).

10. Diagnostics

• Genetic testing: Diagnosis is established via NGS-based inborn-errors-of-immunity gene panels or exome/genome sequencing with TRAF3-targeted variant calling/reanalysis — explicitly how the 2024 cohort was ascertained (reanalysis of 800 existing IEI sequencing datasets). Given the gene's association with CVID-like presentations, TRAF3 should be considered in any CVID/hypogammaglobulinemia gene panel, and clinicians are encouraged to revisit "CVID of unknown cause" cohorts for TRAF3 variants.
• Immunophenotyping (flow cytometry): CD4+ T-cell count and naive/memory subsets, Treg and Tfh proportions, B-cell maturation subsets (naive vs. class-switched memory), immunoglobulin levels (IgG/IgA/IgM), autoantibody panels.
• Functional assays: TRAF3 protein quantification (Western blot) in PBMCs/B cells to confirm haploinsufficient (~50%) vs. dominant-negative (<50%, e.g. ~17.5%) reduction; TLR3-stimulated IFN-β/IL-6 production assays (fibroblast-based, as used in the original HSE study) for suspected IMD132A.
• Imaging: Chest CT for bronchiectasis assessment; abdominal imaging for hepatosplenomegaly/lymphadenopathy.
• Endoscopy/biopsy: For GI inflammation (ileitis, pancolitis) as seen in the index patient.
• Differential diagnosis: Other NF-κB-pathway primary immunodeficiencies — NFKB1 haploinsufficiency (CVID-like), NFKB2 deficiency, CTLA4 haploinsufficiency, TNFAIP3/A20 haploinsufficiency (HA20), LRBA deficiency — all share overlapping combined immunodeficiency-with-autoimmunity phenotypes and should be distinguished by targeted gene panel/exome sequencing. Also distinguish idiopathic CVID (no identified monogenic cause) from monogenic TRAF3-HI, since a subset of "CVID" patients are now understood to actually have TRAF3-HI.
• Screening: No population/newborn screening applicable given rarity; cascade testing of relatives is appropriate given autosomal dominant inheritance and variable expressivity.

11. Outcome/Prognosis

• Malignancy risk: The founding Science Immunology study explicitly reports an increased risk of B-cell malignancy among TRAF3-HI patients, mechanistically consistent with TRAF3's established tumor-suppressor role — chronic non-canonical NF-κB2/pro-survival protein (Mcl1, Pim2, c-Myc) hyperactivation in the heterozygous state provides a plausible intermediate step toward the complete/biallelic TRAF3 loss recurrently observed as a somatic driver in multiple myeloma and B-cell lymphoma. Comparative oncology data reinforce this: germline TRAF3 mutations were found in 17.5% (11/63) of canine B-cell lymphoma cases, with 14.2% lacking any additional somatic TRAF3 mutation, suggesting inherited TRAF3 variants alone can predispose to lymphoma (PMID 25468570).
• Structural/functional sequelae: Bronchiectasis represents a documented, presumably irreversible structural complication of recurrent respiratory infection.
• Mortality/survival: No formal survival statistics are available given the small, recently described cohort; the historical HSE-associated case responded to antiviral treatment, while the M. abscessus-associated case was treatment-resistant, illustrating variable infection-related morbidity.
• Complications: Chronic GI inflammation (ileitis, pancolitis), hepatosplenomegaly, autoimmune manifestations, and immunoglobulin abnormalities requiring ongoing management.
• Prognostic factors: No validated biomarkers for stratifying disease severity/malignancy risk are yet established; age-related TRAF3 decline (independent of the germline variant) is a biologically plausible but clinically unvalidated risk-modifying factor.

12. Treatment

No disease-specific, TRAF3-HI-tailored treatment guideline yet exists (reflecting its very recent characterization); management is inferred to follow the general combined-immunodeficiency-with-autoimmunity paradigm used for related NF-κB-pathway PIDs (e.g., CVID, NFKB1-HI, CTLA4-HI):

• Immunoglobulin replacement therapy (IVIG/SCIG): Documented directly — the 2024 cohort's 3 patients, having previously been diagnosed with CVID, were receiving immunoglobulin replacement therapy for hypogammaglobulinemia and recurrent infections (NCIT:C15986 Pharmacotherapy category; specific product NCIT terms would apply to the IVIG/SCIG agent used).
• Antibiotic prophylaxis/treatment: Implied standard-of-care for recurrent bacterial sinopulmonary infection and bronchiectasis management, and specifically required (with resistance noted) for the M. abscessus pulmonary infection case.
• Antiviral therapy: Standard HSV antiviral treatment (e.g., acyclovir) for herpes simplex encephalitis in the IMD132A phenotype; the reported HSE case "responded to treatment."
• Immunomodulation for autoimmune manifestations: Not explicitly reported for TRAF3-HI patients in the sources retrieved, but by analogy to closely related NF-κB-pathway PIDs (e.g., CTLA4 haploinsufficiency, ALPS), agents such as sirolimus (mTOR inhibitor, effective for refractory autoimmune cytopenias/lymphoproliferation in related PIDs) and rituximab (anti-CD20, B-cell depletion) represent plausible off-label options for autoimmune cytopenia/lymphoproliferation, though no TRAF3-HI-specific outcome data were found.
• Targeted/experimental therapeutics: Given TRAF3's role upstream of NF-κB2/NIK, NIK inhibitors or other non-canonical NF-κB pathway modulators represent a mechanistically rational but currently unvalidated therapeutic avenue; a related mouse study found Syk inhibition limited autoimmunity and abnormal B-cell phenotype/function in B-cell-specific TRAF3-deficient mice (J Immunol, academic.oup.com/jimmunol article), suggesting Syk-pathway targeting as another candidate strategy warranting translational investigation.
• Malignancy surveillance: Given the demonstrated B-cell malignancy risk, ongoing hematologic/oncologic surveillance is a reasonable clinical inference, though no formal surveillance protocol has been published.
• No gene therapy, cell therapy, or disease-specific clinical trials (ClinicalTrials.gov) were identified for TRAF3-HI specifically.

13. Prevention

• Primary prevention: Not applicable in the classic sense (germline monogenic disease); genetic counseling for affected families is appropriate given autosomal dominant inheritance and variable expressivity, including consideration of cascade testing in relatives and reproductive counseling.
• Secondary prevention: Early genetic diagnosis (via IEI panel/exome reanalysis) allows earlier initiation of immunoglobulin replacement and infection-prevention measures, potentially forestalling bronchiectasis and other structural sequelae; routine vaccination status optimization (noting that live vaccines may be contraindicated depending on the degree of immunodeficiency, as in other combined immunodeficiencies) is a standard PID consideration though not TRAF3-HI-specific in the literature reviewed.
• Tertiary prevention: Malignancy surveillance (as above) to enable early detection of B-cell lymphoproliferative transformation.
• No vaccine, chemoprophylactic, or public-health-level prevention strategy specific to TRAF3-HI exists, consistent with its status as an ultra-rare monogenic disorder rather than an infectious or environmentally-driven condition.

14. Other Species / Natural Disease

• Dog (Canis lupus familiaris): The most clinically relevant comparative model — germline and somatic TRAF3 inactivation is a recurrent, naturally occurring feature of canine B-cell lymphoma (cBCL). Somatic TRAF3 mutations (frameshift + truncating SNVs) were found in ~30.2% of a cBCL cohort, and germline TRAF3 mutations in 17.5% (11/63) of cases, with 14.2% of cases carrying only a germline (no somatic) TRAF3 mutation — directly supporting the concept that a single inherited TRAF3 LOF allele predisposes to B-cell malignancy, paralleling concerns for human TRAF3-HI patients (PMID 25468570, Blood). This makes naturally occurring canine BCL a valuable spontaneous large-animal comparative model for the human malignancy-risk arm of TRAF3-HI.
• Taxonomy: Canis lupus familiaris (NCBITaxon:9615).
• Orthology: TRAF3 is highly conserved across mammals; canine TRAF3 shares the same NF-κB-regulatory function as human TRAF3.
• Zoonotic potential: Not applicable — this is a non-communicable, germline genetic condition, not a transmissible disease.

15. Model Organisms

• Mouse (Mus musculus), full-body Traf3 knockout: Per MGI (marker MGI:108041), homozygous Traf3-null mice show progressive runting, hypoglycemia, and depletion of peripheral white blood cells, dying by ~10 days of age; lethally irradiated mice reconstituted with mutant hematopoietic cells show impaired T-dependent antibody responses — establishing TRAF3 as essential for immune and metabolic homeostasis, and explaining why disease-causing human variants are invariably heterozygous (complete biallelic loss is likely embryonically/perinatally incompatible with survival, analogous to the mouse).
• Mouse, B-cell-conditional heterozygous knockout (B-Traf3+/−): The key genetic model directly modeling human haploinsufficiency (Hornick et al., 2025, PNAS). Findings: 40–50% reduction of TRAF3 protein/mRNA in splenic B cells; dose-intermediate increases in spleen weight, splenic B-cell number, NF-κB2 (p52) activation, plasma-cell numbers (splenic, not marrow), and pro-survival protein expression (Mcl1, Pim2, c-Myc, Hxk2) relative to wild-type and full knockout; prolonged in vitro B-cell survival through day 3 (dying by day 5); elevated phospho-STAT3(Y705) after IL-6 stimulation.
• Mouse, B-cell-specific complete Traf3 knockout: Used in earlier mechanistic work (e.g., leu2011309, Leukemia journal) showing that complete B-lineage Traf3 deletion drives spontaneous B-lymphoma development in mice — modeling the malignancy end of the phenotypic spectrum; Syk inhibition was shown to limit the resulting autoimmunity and abnormal B-cell phenotype in this model.
• Aged wild-type mice: Used as a model of physiological TRAF3 decline — aged (≥16 months) vs. young (≤3 months) mouse B cells show reduced TRAF3 protein (mirroring the human aging data), reversible acutely by proteasome inhibition (bortezomib), directly linking normal aging biology to the same pathway disrupted genetically in TRAF3-HI.
• Model limitations: Full knockout mice die neonatally and cannot model the chronic, decades-long human disease course; heterozygous B-cell-conditional mice best model the dosage-sensitive human phenotype but do not capture T-cell dysregulation, GI inflammation, or CNS (HSE-susceptibility) aspects of the human syndrome, which currently lack dedicated animal models. No zebrafish, Drosophila, C. elegans, iPSC, or organoid TRAF3-HI-specific disease models were identified in this search.
• Resources: MGI (Traf3 marker MGI:108041; targeted alleles e.g. MGI:3722126 [tm1Bshp], MGI:2135257 [tm1Bal], MGI:3777325 [tm1.1Rbr]); Cyagen commercial Traf3-KO mouse model.

Summary of Key Ontology Term Suggestions

Notes on Evidentiary Gaps

• No confirmed MONDO ID was identified for this specific entity via search; this should be independently verified in the current Mondo release before curation.
• Direct primary-source full text for the founding Science Immunology paper (abn3800) and the Journal of Clinical Immunology CVID cohort paper (10.1007/s10875-024-01833-3) could not be fetched directly (paywalled/403); the information above for these two papers is drawn from search-result summaries and secondary citations rather than verified direct quotes from the primary text. Exact-quote snippets for dismech evidence items should be re-verified against the primary PMID/DOI sources (or PMC full text if available) before being entered into evidence blocks, per the project's evidence-integrity requirements.
• Quantitative epidemiological data (prevalence/incidence), formal quality-of-life measures, and a validated diagnostic/treatment algorithm are not yet available in the literature, consistent with this being a very recently characterized (2022–2024), ultra-rare monogenic disorder.

Sources: - Human TRAF3 Adaptor Molecule Deficiency Leads to Impaired Toll-like Receptor 3 Response and Susceptibility to Herpes Simplex Encephalitis (PubMed, PMID 20832341) - Human TRAF3 Adaptor Molecule Deficiency... (Immunity/Cell.com full text) - Immunodeficiency, autoimmunity, and increased risk of B cell malignancy in humans with TRAF3 mutations (Science Immunology, abn3800) - Heterozygous Predicted Loss-of-function Variants of TRAF3 in Patients with Common Variable Immunodeficiency (J Clin Immunol, PMID 39579173) - Reduction of TRAF3 by heterozygosity or aging impacts B cell function (PNAS, PMID 40773231) - Reduction of TRAF3 by heterozygosity or aging impacts B cell function (PMC free full text) - OMIM #621096 — IMMUNODEFICIENCY 132B; IMD132B - OMIM #614849 — IMMUNODEFICIENCY 132A; IMD132A - OMIM *601896 — TNF RECEPTOR-ASSOCIATED FACTOR 3; TRAF3 - Dominant Negative TRAF3 Variant With Recurrent Mycobacterium abscessus Infection and Bronchiectasis (Open Forum Infectious Diseases, PMID 36004314) - Genetic inactivation of TRAF3 in canine and human B-cell lymphoma (Blood, PMID 25468570) - Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in mice (Leukemia) - TRAF3: A novel regulator of mitochondrial physiology and metabolic pathways in B lymphocytes (Frontiers in Oncology, PMC9911533) - Syk inhibition limits autoimmunity and abnormal B cell phenotype and function in mice with B cell-specific TRAF3 deficiency (Journal of Immunology) - Traf3 MGI Mouse Gene Detail — MGI:108041 - TRAF3 Gene — GeneCards - TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-κB pathway (PNAS) - Molecular basis for CD40 signaling mediated by TRAF3 (PNAS) - Immunodeficiency 132b — MalaCards